Click to watch the report overview video for a comprehensive explanation of each section of the Prolaris Test report.
The Prolaris Test is a cell-cycle proliferation-based biomarker that determines how aggressive your patients cancer is behaving. The Prolaris Test eliminates guesswork around cancer risk by combining clinical and pathological features with a personalized tumor aggressiveness score.
Click the number of each section to learn more.
Hover/tap on each section of the sample Prolaris Biopsy Report to learn more about each segment.
The Prolaris Molecular Score is calculated by measuring the expression of 31 cell cycle progression (CCP) genes in the tumor. This predicts the behavior of the tumor. The majority of Prolaris Molecular Scores fall between 1-11, with a higher score indicating more aggressive cancer.
Clinical variables and the Prolaris Molecular Score are combined to calculate a patient’s risk assessment.
Men with low Prolaris Test scores are identified as being appropriate for active surveillance and may initially be spared unnecessary treatment, significantly impacting their quality of life.
Men who are NOT considered appropriate for active surveillance are identified as candidates for single-modal therapy, which is defined as one therapy planned at the treatment onset.
Men who are not considered appropriate to pursue single-modal treatment are identified as candidates for multi-modal therapy, which is defined as either radiation with androgen deprivation or surgery with intensified therapy per guideline recommendations.
A patient’s 10-year risk of disease specific mortality when choosing Active Surveillance. See risk assessment detail page for more information.
A patient’s 10-year risk of developing metastatic cancer when choosing single-modal treatment like surgery or radiation.
A patient’s 10–year risk of metastasis when choosing Radiation Therapy AND Androgen Deprivation Therapy (ADT)
Patients with a 10-year risk of Disease Specific Mortality (DSM) within the green box are considered candidates for AS. This threshold was validated on conservatively managed patients with DSM as the primary outcome.
For a patient considering single modal treatment, the 10-year risk of metastasis is shown within the blue box. This threshold was validated on patients treated with single-modal therapy, with metastasis as the primary endpoint.
Absolute Risk Reduction is an individualized assessment of how adding hormone therapy (ADT) to Radiation Therapy (RT) may reduce a patient’s risk of metastasis over the next 10 years.
The patient’s risk of Disease Specific Mortality or metastasis is represented with a person icon. This person is compared to other patients within their NCCN risk group (based on clinical parameters alone). The average DSM risk of each NCCN category is shown with a triangle. The active surveillance threshold is indicated by a dashed line The multi-modal threshold is indicated with a dotted line.
The test description and references are provided on the final page of the report.
©2025 Myriad Genetics, Inc. Myriad Genetics, Prolaris and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.